Limitations of current chemotherapy and future of nanoformulation-based amb delivery for visceral leishmaniasis — an updated review

HIGHLIGHTS

  • who: . and colleagues from the Argentina Ben-Gurion University of the Negev have published the paper: Limitations of current chemotherapy and future of nanoformulation-based AmB delivery for visceral leishmaniasis u2014 An updated review, in the Journal: (JOURNAL)

SUMMARY

    About 1.5-2 million new cases are diagnosed annually, with 70,000 deaths (Torres-Guerrero et_al, 2017). The LD complex causes VL (van Griensven and Diro, 2012; Singh et_al, 2016) and LD is a protozoan parasite that causes leishmaniasis in Asia and Eastern Africa (Alves et_al, 2018; Selvapandiyan et_al, 2019). Every year, the . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?